More than 90% of EU and EEA pharmacovigilance inspections occur through national inspection programmes. Therefore, companies need inspection-ready systems that work every day, not only before audits. Pharmacovigilance consultants can help identify gaps, strengthen controls, and support compliant pharmacovigilance services. As regulatory expectations evolve, focused expertise can protect drug safety and improve inspection readiness.
Table of Contents
What Do Pharmacovigilance Consultants Do?
Pharmacovigilance consultants help pharmaceutical companies strengthen drug safety systems and meet regulatory requirements. They can support strategy, daily operations, quality processes, compliance activities, and inspection preparation. In addition, their expertise can help identify system gaps and improve the consistency of pharmacovigilance processes. However, external support does not transfer regulatory accountability. The marketing authorisation holder remains responsible for maintaining an effective and compliant pharmacovigilance system.
Why External PV Expertise Matters for Compliance?
External pharmacovigilance expertise becomes especially valuable when regulatory complexity, limited resources, outsourcing, or system changes expose control gaps. These weaknesses can affect documentation, oversight, CAPA, and inspection readiness. Therefore, specialist support can help teams identify risks early and strengthen the pharmacovigilance quality system. In addition, an independent review can reveal issues that internal teams may overlook before they become inspection findings.
The infographic shows how pharmacovigilance gaps can develop into inspection risks and where stronger controls can improve compliance.
4 Areas Where Pharmacovigilance Consultants Add Regulatory Value
Pharmacovigilance consulting services can add the most value where regulatory requirements meet complex operational processes. They help companies identify weaknesses, strengthen controls, and create evidence that supports regulatory compliance. In addition, specialist input can improve oversight without replacing the MAH’s responsibility for the pharmacovigilance system.
Four areas are especially important when companies need stronger control, clearer oversight, and sustainable inspection readiness.
- Strengthening the Pharmacovigilance Quality System (Available PDF)
- Keeping the PSMF and QPPV Oversight Inspection-Ready (Available PDF)
- Turning PV Audits and CAPA Into Sustainable Control (Available PDF)
- Controlling Outsourced PV Activities and Third Parties (Available PDF)
Strengthening the Pharmacovigilance Quality System (Available PDF)
A pharmacovigilance quality system should define clear responsibilities, controlled processes, trained personnel, monitoring, and documented evidence. Consultants can help identify weaknesses and strengthen these controls so the system remains effective and inspection-ready.
Keeping the PSMF and QPPV Oversight Inspection-Ready (Available PDF)
The PSMF should accurately describe the pharmacovigilance system, including QPPV responsibilities, processes, performance, and changes. Strong governance helps keep this information current, accessible, and ready for regulatory inspection.
Turning PV Audits and CAPA Into Sustainable Control (Available PDF)
PV audits should identify significant weaknesses and support risk-based corrective action. CAPA becomes effective when teams address root causes, implement actions, monitor results, and retain evidence of completion.
Controlling Outsourced PV Activities and Third Parties (Available PDF)
Outsourcing PV activities does not remove the MAH’s responsibility for oversight and compliance. Clear agreements, documented responsibilities, accessible records, and ongoing vendor control are essential for managing third-party risk.
When Should a Company Use Pharmacovigilance Consulting Services?
A company may need external pharmacovigilance expertise when internal capacity or specialist knowledge no longer matches regulatory demands. For example, inspections, system changes, outsourcing, or unresolved compliance issues can increase operational risk. Therefore, pharmacovigilance consulting services can provide focused support during complex or high-risk periods. However, companies should use external expertise to strengthen internal control, not replace regulatory accountability.
The infographic shows the main operational and regulatory triggers that can make external pharmacovigilance support valuable for a pharmaceutical company.
How Should You Evaluate Pharmacovigilance Consulting Services?
Choosing a pharmacovigilance consultant should focus on evidence, not broad claims. First, verify relevant GVP experience and technical competence for the activities involved. In addition, assess how the consultant manages inspection readiness, documentation, governance, and regulatory risks. Finally, confirm that the project will leave your internal team with sustainable controls and clear ownership.
The table below summarizes the four most important criteria pharmaceutical companies should verify before selecting external pharmacovigilance expertise.
| Evaluation Area | What to Verify | Evidence to Request | Why It Matters |
|---|---|---|---|
|
Regulatory experience |
Relevant GVP knowledge and experience in applicable markets |
Qualifications and comparable project experience |
Supports compliant regulatory decisions |
|
Technical PV capability |
Expertise relevant to the required PV processes and systems |
Technical experience and specialist credentials |
Ensures support matches the actual PV risks |
|
Inspection and audit knowledge |
Experience with inspections, audits, CAPA, and remediation |
Audit approach and inspection-support methodology |
Strengthens inspection readiness and corrective actions |
|
Governance and knowledge transfer |
Clear responsibilities, oversight, handover, and internal ownership |
Governance plan, responsibility matrix, and handover records |
Helps the MAH retain control and sustain compliance |
Final Words
EMA recorded 10 CHMP or CVMP-requested pharmacovigilance inspections in 2025, compared with 18 in 2024. However, this shift reflects the risk-based inspection cycle rather than lower regulatory oversight. Therefore, companies should treat inspection readiness as a continuous control activity. Pharmacovigilance consultants can support this work by strengthening evidence, governance, and sustainable compliance.
Quality Management System
We work with pharmaceutical teams to design, implement, and run effective Quality Management Systems, covering change control, CAPA, deviations, and audits to support consistent GMP compliance.
FAQ
No. An MAH may outsource pharmacovigilance activities, but it retains responsibility for the pharmacovigilance system, regulatory compliance, data integrity, and appropriate oversight. Contracts should also ensure access to records and inspection support.
Check relevant GVP experience, technical expertise, inspection and audit knowledge, governance controls, and knowledge-transfer capability. The consultant should also understand PSMF requirements, QPPV oversight, CAPA, and the company’s specific pharmacovigilance quality system.
The MAH should maintain current agreements, defined responsibilities, accessible PV records, an accurate PSMF, vendor oversight evidence, CAPA records, and clear escalation processes. Inspectors may assess outsourced activities during an MAH inspection, so documentation and third-party support must remain available.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.